Checked
Federal dataHealth
Plerixafor
Published by U.S. Food and Drug Administration · Updated 03/17/2025 · Yearly
- Last updated
- 03/17/2025
- First published 09/16/2016
- Update frequency
- Yearly
- Formats
- Web only
- Coverage
- Nationwide
- Federal data
About this dataset
Plerixafor is a prescription medication that helps mobilize stem cells from the bone marrow into the bloodstream, often used before stem cell transplants in patients with certain cancers or blood disorders. It's administered as a subcutaneous injection, available as a 24 mg/1.2 mL solution (20 mg/mL) from Dr. Reddy's Laboratories. This information was generated using AI and is provided for informational and research purposes only.
Files and access
Links open the official government source
- Plerixaforaccessdata.fda.govWeb page
Links open outside websites we do not control.
Details
- Publisher
- U.S. Food and Drug Administration
- Listed on
- Data.gov
- Platform
- Data.gov catalog
- License
- https://open.fda.gov/license
- Keywords
- drug-information, drug-manufacturers, health-care, medications, prescription-drugs
More from U.S. Food and Drug Administration
- Drug Establishments Current Registration SiteU.S. Food and Drug AdministrationThe Drug Establishments Current Registration Site (DECRS) is a database of current information submitted by drug firms to register establishments (facilities) which manufacture, prepare, propagate, compound or process drugs that are commercially distributed inZIPUpdated 07/16/2025Quarterly
- Drugs@FDA DatabaseU.S. Food and Drug AdministrationInformation about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letZIPUpdated 07/16/2025Daily
- Clinical Investigator Inspector List (CLIIL)U.S. Food and Drug AdministrationThe Clinical Investigator Inspection List (CLIIL) contains names, addresses, and other pertinent information gathered from inspections of clinical investigators who have performed studies with investigational new drugs. The list contains information on inspectZIPUpdated 07/16/2025Quarterly
- Current and Resolved Drug Shortages and Discontinuations Reported to FDAU.S. Food and Drug AdministrationInformation provided to FDA by manufacturers about current drugs in shortage, resolved shortages, and discontinuations of specific drug products.Updated 07/16/2025Weekly
- Approved Animal Drug Products (Green Book)U.S. Food and Drug AdministrationOn November 16, 1988, the President of the United States signed into law the Generic Animal Drug and Patent Restoration Act (GADPTRA). Among its major provisions, the Act extends eligibility for submission of Abbreviated New Animal Drug Applications (ANADAs) tUpdated 07/16/2025Yearly
- National Drug Code DirectoryOn DatenUSU.S. Food and Drug AdministrationThe Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See SectionZIPUpdated 11/14/2013
- FDA Adverse Event Reporting System (FAERS): Latest Quartely Data FilesU.S. Food and Drug AdministrationThe FDA Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to FDA. The database is designed to support the FDA's post-marketing safety surveillance program for drug and therapeZIPUpdated 08/16/2013
- Adverse Event Reporting System (AERS)U.S. Food and Drug AdministrationThe Adverse Event Reporting System (AERS) is a computerized information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products. The FDA uses AERS to monitor for new adverse evenZIPUpdated 01/01/2004
Similar data from other publishers
- PlerixaforState of VirginiaPlerixafor is a prescription medication used to help mobilize hematopoietic stem cells in the blood, often before stem cell transplants. It's administered as a subcutaneous injection in a 24 mg/1.2 mL solution. Manufactured by Eugia US LLC under ANDA213672. ThUpdated 06/12/2026
- PlerixaforState of VirginiaPlerixafor is a prescription medication that helps mobilize stem cells from the bone marrow into the bloodstream, often used before stem cell transplants in patients with certain cancers or blood disorders. It's administered as a subcutaneous injection, availaUpdated 06/12/2026
- PlerixaforState of VirginiaPlerixafor is a prescription medication used to help mobilize hematopoietic stem cells in the blood, often before stem cell transplants. It's administered as a subcutaneous injection in a 24 mg/1.2 mL solution. Manufactured by Eugia US LLC under ANDA213672. ThUpdated 03/24/2026
- PlerixaforState of VirginiaPlerixafor is a prescription medication that helps mobilize stem cells from the bone marrow into the bloodstream, often used before stem cell transplants in patients with certain cancers or blood disorders. It's administered as a subcutaneous injection, availaUpdated 03/24/2026
- PlerixaforState of VirginiaPlerixafor is a prescription drug that helps mobilize hematopoietic stem cells in the blood, aiding their collection for transplantation in patients with certain cancers or blood disorders. It's given as a subcutaneous injection, with each dose containing 24 mUpdated 03/24/2026
Frequently asked questions
- Who publishes Plerixafor?
- U.S. Food and Drug Administration, part of U.S. Department of Health & Human Services, publishes this dataset on Data.gov.
- How often is it updated?
- The publisher lists the update frequency as yearly. The last update was on 03/17/2025.
- How do I download it?
- Use the official source link above to view or request the data.
Source: Data.gov · Last updated 10/24/2026 · Listing only; the data stays with the publisher